Last reviewed · How we verify
Risperdal,reminyl
Risperdal,reminyl is a Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl) Small molecule drug developed by Jinan Mental Hospital. It is currently FDA-approved for Schizophrenia (Risperdal), Bipolar disorder (Risperdal), Irritability associated with autism spectrum disorder (Risperdal).
Risperdal is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, while Reminyl (galantamine) is a cholinesterase inhibitor that increases acetylcholine levels in the brain.
Risperdal is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, while Reminyl (galantamine) is a cholinesterase inhibitor that increases acetylcholine levels in the brain. Used for Schizophrenia (Risperdal), Bipolar disorder (Risperdal), Irritability associated with autism spectrum disorder (Risperdal).
At a glance
| Generic name | Risperdal,reminyl |
|---|---|
| Sponsor | Jinan Mental Hospital |
| Drug class | Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl) |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology (Risperdal); Neurology (Reminyl) |
| Phase | FDA-approved |
Mechanism of action
Risperdal reduces dopamine and serotonin signaling to treat psychotic symptoms and mood disturbances in schizophrenia and bipolar disorder. Reminyl inhibits acetylcholinesterase to elevate acetylcholine concentrations, improving cognitive function in Alzheimer's disease. These are two distinct drugs with different mechanisms and therapeutic targets.
Approved indications
- Schizophrenia (Risperdal)
- Bipolar disorder (Risperdal)
- Irritability associated with autism spectrum disorder (Risperdal)
- Mild to moderate Alzheimer's disease (Reminyl)
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Weight gain
- Hyperprolactinemia
- Sedation
- Nausea (Reminyl)
- Diarrhea (Reminyl)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperdal,reminyl CI brief — competitive landscape report
- Risperdal,reminyl updates RSS · CI watch RSS
- Jinan Mental Hospital portfolio CI
Frequently asked questions about Risperdal,reminyl
What is Risperdal,reminyl?
How does Risperdal,reminyl work?
What is Risperdal,reminyl used for?
Who makes Risperdal,reminyl?
What drug class is Risperdal,reminyl in?
What development phase is Risperdal,reminyl in?
What are the side effects of Risperdal,reminyl?
What does Risperdal,reminyl target?
Related
- Drug class: All Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl) drugs
- Target: All drugs targeting Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
- Manufacturer: Jinan Mental Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology (Risperdal); Neurology (Reminyl)
- Indication: Drugs for Schizophrenia (Risperdal)
- Indication: Drugs for Bipolar disorder (Risperdal)
- Indication: Drugs for Irritability associated with autism spectrum disorder (Risperdal)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing